WMS Partners’s Lexicon Pharmaceuticals LXRX Stock Holding History

WMS Partners’s Portfolio LXRX Stock Details LXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-11,200	Closed	-$66K	–	264
2021 Q1	$66K	Hold	11,200	–	–	0.02%	221
2020 Q4	$38K	Hold	11,200	–	–	0.01%	235
2020 Q3	$16K	Hold	11,200	–	–	﹤0.01%	234
2020 Q2	$22K	Hold	11,200	–	–	﹤0.01%	210
2020 Q1	$22K	Hold	11,200	–	–	0.01%	189
2019 Q4	$46K	Hold	11,200	–	–	0.01%	217
2019 Q3	$34K	Hold	11,200	–	–	0.01%	221
2019 Q2	$70K	Hold	11,200	–	–	0.02%	212
2019 Q1	$62K	Hold	11,200	–	–	0.02%	197
2018 Q4	$74K	Hold	11,200	–	–	0.02%	178
2018 Q3	$120K	Hold	11,200	–	–	0.01%	215
2018 Q2	$134K	Hold	11,200	–	–	0.02%	218
2018 Q1	$96K	Hold	11,200	–	–	0.01%	216
2017 Q4	$111K	Hold	11,200	–	–	0.01%	230
2017 Q3	$138K	Buy	11,200 +1,200	+12%	+$17.7K	0.02%	209
2017 Q2	$165K	Hold	10,000	–	–	0.02%	206
2017 Q1	$143K	Hold	10,000	–	–	0.02%	195
2016 Q4	$138K	Hold	10,000	–	–	0.02%	183
2016 Q3	$181K	Buy	+10,000	New	+$161K	0.02%	186
2016 Q2	–	Sell	-10,000	Closed	-$120K	–	213
2016 Q1	$120K	Hold	10,000	–	–	0.02%	191
2015 Q4	$133K	Buy	+10,000	New	+$123K	0.02%	197

Other funds holding LXRX

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Pinnacle Associates New York $9.16B AUM 63.5% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

WMS Partners's LXRX Position: Q2 2021 in Review

WMS Partners sold out of Lexicon Pharmaceuticals (LXRX) in Q2 2021, closing a stake of 11,200 shares — an estimated $66K sold.

WMS Partners first reported a position in LXRX in Q4 2015 and held it in 21 quarters. The position peaked at $181K in Q3 2016. 107 funds tracked by Wall St. Rank hold LXRX as of Q2 2021.

WMS Partners reported no remaining Lexicon Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
WMS Partners sold 11,200 Lexicon Pharmaceuticals shares in Q2 2021, an estimated $66K.
WMS Partners first reported a position in Lexicon Pharmaceuticals in Q4 2015 and held it in 21 quarters.
WMS Partners's Lexicon Pharmaceuticals position peaked at $181K in Q3 2016.
107 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q2 2021.

Based on WMS Partners's 13F filing for Q2 2021, filed 13 Aug 2021.